Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles

[Display omitted] Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of layer-by-layer assembled gold nanoparticles (LbL-AuNP) containing anti-STAT3 siRNA and imatinib mesylate (IM) to treat melanoma. The combination treatment...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 525; no. 2; pp. 407 - 417
Main Authors Labala, Suman, Jose, Anup, Chawla, Sumeet Rajesh, Khan, Mohammed Shareef, Bhatnagar, Shubhmita, Kulkarni, Onkar Prakash, Venuganti, Venkata Vamsi Krishna
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 20.06.2017
Subjects
Animals
Cell Line, Tumor
Co-delivery
Gold
Gold nanoparticle
Imatinib mesylate
Imatinib Mesylate - administration & dosage
Iontophoresis
Melanoma
Melanoma, Experimental - genetics
Melanoma, Experimental - therapy
Metal Nanoparticles - chemistry
Mice
RNA, Small Interfering - administration & dosage
STAT3 siRNA
STAT3 Transcription Factor - genetics
LbL-AuNP
PVP
MTT
SA
SC
DMEM
Iontophoresis
FITC
PDI
DSC
FBS
FTIR
Co-delivery
Cy3
Gold nanoparticle
PBS
IM
VEGF
STAT3
Melanoma
Imatinib mesylate
DAPI
PKC
siRNA
PAMAM
STAT3 siRNA
CS
RP-HPLC
Online AccessGet full text

Cover

Abstract [Display omitted] Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of layer-by-layer assembled gold nanoparticles (LbL-AuNP) containing anti-STAT3 siRNA and imatinib mesylate (IM) to treat melanoma. The combination treatment with STAT3 siRNA and IM in B16F10 melanoma cells showed greater suppression of STAT3 protein, decreased cell viability and increased apoptotic events compared with LbL-AuNP containing either STAT3 siRNA or IM. In vivo efficacy studies in melanoma tumor bearing mice showed that non-invasive topical iontophoretic administration (0.5mA/cm2) of LbL-AuNP was comparable with intratumoral administration. Co-delivery of STAT3 siRNA and IM using LbL-AuNP showed significant (p<0.05) reduction in percentage tumor volume, tumor weight and suppressed STAT3 protein expression compared with either STAT3 siRNA or IM loaded LbL-AuNP. Taken together, LbL-AuNP can be developed as nanocarrier system for co-delivery of siRNA and small molecule drugs for topical iontophoretic delivery.
AbstractList Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of layer-by-layer assembled gold nanoparticles (LbL-AuNP) containing anti-STAT3 siRNA and imatinib mesylate (IM) to treat melanoma. The combination treatment with STAT3 siRNA and IM in B16F10 melanoma cells showed greater suppression of STAT3 protein, decreased cell viability and increased apoptotic events compared with LbL-AuNP containing either STAT3 siRNA or IM. In vivo efficacy studies in melanoma tumor bearing mice showed that non-invasive topical iontophoretic administration (0.5mA/cm ) of LbL-AuNP was comparable with intratumoral administration. Co-delivery of STAT3 siRNA and IM using LbL-AuNP showed significant (p<0.05) reduction in percentage tumor volume, tumor weight and suppressed STAT3 protein expression compared with either STAT3 siRNA or IM loaded LbL-AuNP. Taken together, LbL-AuNP can be developed as nanocarrier system for co-delivery of siRNA and small molecule drugs for topical iontophoretic delivery.
[Display omitted] Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of layer-by-layer assembled gold nanoparticles (LbL-AuNP) containing anti-STAT3 siRNA and imatinib mesylate (IM) to treat melanoma. The combination treatment with STAT3 siRNA and IM in B16F10 melanoma cells showed greater suppression of STAT3 protein, decreased cell viability and increased apoptotic events compared with LbL-AuNP containing either STAT3 siRNA or IM. In vivo efficacy studies in melanoma tumor bearing mice showed that non-invasive topical iontophoretic administration (0.5mA/cm2) of LbL-AuNP was comparable with intratumoral administration. Co-delivery of STAT3 siRNA and IM using LbL-AuNP showed significant (p<0.05) reduction in percentage tumor volume, tumor weight and suppressed STAT3 protein expression compared with either STAT3 siRNA or IM loaded LbL-AuNP. Taken together, LbL-AuNP can be developed as nanocarrier system for co-delivery of siRNA and small molecule drugs for topical iontophoretic delivery.
Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of layer-by-layer assembled gold nanoparticles (LbL-AuNP) containing anti-STAT3 siRNA and imatinib mesylate (IM) to treat melanoma. The combination treatment with STAT3 siRNA and IM in B16F10 melanoma cells showed greater suppression of STAT3 protein, decreased cell viability and increased apoptotic events compared with LbL-AuNP containing either STAT3 siRNA or IM. In vivo efficacy studies in melanoma tumor bearing mice showed that non-invasive topical iontophoretic administration (0.5mA/cm2) of LbL-AuNP was comparable with intratumoral administration. Co-delivery of STAT3 siRNA and IM using LbL-AuNP showed significant (p&lt;0.05) reduction in percentage tumor volume, tumor weight and suppressed STAT3 protein expression compared with either STAT3 siRNA or IM loaded LbL-AuNP. Taken together, LbL-AuNP can be developed as nanocarrier system for co-delivery of siRNA and small molecule drugs for topical iontophoretic delivery.
Author Kulkarni, Onkar Prakash
Venuganti, Venkata Vamsi Krishna
Labala, Suman
Jose, Anup
Khan, Mohammed Shareef
Bhatnagar, Shubhmita
Chawla, Sumeet Rajesh
Author_xml – sequence: 1
  givenname: Suman
  surname: Labala
  fullname: Labala, Suman
– sequence: 2
  givenname: Anup
  surname: Jose
  fullname: Jose, Anup
– sequence: 3
  givenname: Sumeet Rajesh
  surname: Chawla
  fullname: Chawla, Sumeet Rajesh
– sequence: 4
  givenname: Mohammed Shareef
  surname: Khan
  fullname: Khan, Mohammed Shareef
– sequence: 5
  givenname: Shubhmita
  surname: Bhatnagar
  fullname: Bhatnagar, Shubhmita
– sequence: 6
  givenname: Onkar Prakash
  surname: Kulkarni
  fullname: Kulkarni, Onkar Prakash
– sequence: 7
  givenname: Venkata Vamsi Krishna
  surname: Venuganti
  fullname: Venuganti, Venkata Vamsi Krishna
  email: vamsi@hyderabad.bits-pilani.ac.in, vamsi.venuganti@gmail.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28373100$$D View this record in MEDLINE/PubMed
BookMark eNqFkEtvEzEUhS1U1KalPwHkJZsZbN_MeLJCUdUHUgUShLXl2Netoxl7sGda5d_XUQJbVmdzHjrfJTkLMSAhHzmrOePtl13td-OzTkMtGJc1g5p18h1Z8E5CBUvZnpEFA9lVDZdwQS5z3jHGWsHhnFyIDiRwxhbk9dY5NJN_QTpgr0McNDU6GEw0z-OYMGcfA93uaZEpjs8x4eQNNbGy2JdY2tPo6K_NegM0-5_f11QHS_2gJx_8ls7Zhyf6FHtLQ2kfdSrpHvMH8t7pPuP1Sa_I77vbzc1D9fjj_tvN-rEyS-BT1RhwXFgAJ5mx5ahzYiWtWa0kGNEAF6vOad5qLhommTXbloEQDtuuaaFhcEU-H3vHFP_MmCc1-GywL1cxzlnxrlvythHyYG2OVpNizgmdGlP5kfaKM3VgrnbqxFwdmCsGqjAvuU-niXk7oP2X-gu5GL4eDViOvnhMKhuPhbH1qbBXNvr_TLwBF7yXxw
CitedBy_id crossref_primary_10_3390_nano11102467
crossref_primary_10_1016_j_envres_2023_116458
crossref_primary_10_1016_j_ijpharm_2018_12_022
crossref_primary_10_3390_chemengineering5040069
crossref_primary_10_3390_pharmaceutics16020255
crossref_primary_10_1016_j_jddst_2023_104394
crossref_primary_10_1038_s41598_019_40904_z
crossref_primary_10_3390_cancers12082111
crossref_primary_10_1007_s13346_022_01138_1
crossref_primary_10_1208_s12249_023_02546_3
crossref_primary_10_1080_21691401_2018_1430585
crossref_primary_10_3390_pharmaceutics12111101
crossref_primary_10_1002_tcr_201700061
crossref_primary_10_1007_s12010_023_04597_5
crossref_primary_10_1016_j_jddst_2021_102332
crossref_primary_10_1016_j_ijpharm_2022_122122
crossref_primary_10_3390_ijms22126538
crossref_primary_10_1007_s40257_019_00452_8
crossref_primary_10_1016_j_addr_2024_115198
crossref_primary_10_3389_fphar_2024_1389922
crossref_primary_10_3390_pharmaceutics13070960
crossref_primary_10_1080_09205063_2022_2054399
crossref_primary_10_1016_j_addr_2017_12_014
crossref_primary_10_1039_D2CC04826D
crossref_primary_10_1039_C8TB02484G
crossref_primary_10_1016_j_ejpb_2023_02_002
crossref_primary_10_1016_j_ijpharm_2019_119010
crossref_primary_10_3390_pharmaceutics15092349
crossref_primary_10_3389_fnano_2021_644023
crossref_primary_10_1007_s00432_018_2726_1
crossref_primary_10_1051_e3sconf_202448803020
crossref_primary_10_1016_j_addr_2020_06_010
crossref_primary_10_1016_j_semcancer_2022_02_022
crossref_primary_10_1016_j_ejps_2023_106476
crossref_primary_10_3390_pharmaceutics10040204
crossref_primary_10_1016_j_tetlet_2017_10_065
crossref_primary_10_3390_ma12050766
crossref_primary_10_1016_j_semcancer_2023_01_002
crossref_primary_10_3390_jcm9020318
crossref_primary_10_3390_app10113824
crossref_primary_10_1016_j_xjidi_2022_100103
crossref_primary_10_1016_j_ejphar_2020_173633
crossref_primary_10_1016_j_ijpharm_2021_120888
crossref_primary_10_3389_fphar_2021_687399
crossref_primary_10_1016_j_jallcom_2020_156604
crossref_primary_10_1016_j_jconrel_2024_06_013
crossref_primary_10_1002_jgm_3089
crossref_primary_10_3390_cells8101158
crossref_primary_10_3389_fphar_2023_1111991
crossref_primary_10_1248_bpb_b22_00746
crossref_primary_10_1002_mco2_124
crossref_primary_10_1016_j_ijpharm_2017_05_010
crossref_primary_10_1016_j_jddst_2022_103964
crossref_primary_10_1016_j_envres_2023_115673
crossref_primary_10_1016_j_addr_2020_02_005
crossref_primary_10_1016_j_ejphar_2021_174639
crossref_primary_10_3390_bioengineering9100576
crossref_primary_10_3390_cancers14204980
crossref_primary_10_3389_fbioe_2019_00113
crossref_primary_10_1016_j_tibtech_2020_07_012
crossref_primary_10_3390_pharmaceutics14122787
crossref_primary_10_3390_jnt5020003
crossref_primary_10_1016_j_ejpb_2019_02_012
crossref_primary_10_3389_fonc_2019_00048
crossref_primary_10_1016_j_cej_2022_134569
crossref_primary_10_1021_acsabm_0c00893
crossref_primary_10_1208_s12249_017_0833_y
crossref_primary_10_3390_ijms22158037
crossref_primary_10_1002_biot_201900408
crossref_primary_10_1016_j_envres_2023_116649
crossref_primary_10_1016_j_cis_2019_101989
crossref_primary_10_2174_0929867325666181116143713
crossref_primary_10_1016_j_carbpol_2021_118427
crossref_primary_10_1186_s12951_024_02580_8
crossref_primary_10_1248_bpb_b22_00873
Cites_doi 10.1016/j.ijpharm.2010.08.022
10.1016/j.biomaterials.2009.11.003
10.1016/j.canlet.2005.03.033
10.1016/S0168-3659(99)00132-7
10.1200/JCO.1986.4.9.1295
10.1146/annurev.med.53.082901.103929
10.1200/JCO.2012.47.7836
10.3109/10717544.2013.867381
10.1016/j.biomaterials.2012.10.057
10.1038/srep21731
10.1093/annonc/mdg731
10.2340/00015555-2035
10.1016/S0092-8674(02)00762-6
10.1001/jamaoncol.2015.0565
10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S
10.1166/jbn.2015.2139
10.1200/JCO.2011.41.0639
10.1016/j.tips.2013.06.005
10.1021/mp5007163
10.1038/onc.2013.34
10.1038/jid.2013.32
10.7326/0003-4819-73-6-881
10.1016/j.ijpharm.2015.04.056
10.1038/483531a
10.1038/nbt.1504
10.1038/nature05661
10.1007/s12032-009-9192-1
10.1039/C4NR05241B
10.1038/nrc.2016.37
10.1002/ijc.29210
10.1016/j.colsurfb.2016.05.076
10.3892/ijo.2014.2481
10.1056/NEJMoa1406037
10.1016/S0928-0987(01)00167-1
ContentType Journal Article
Copyright 2017 Elsevier B.V.
Copyright © 2017 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2017 Elsevier B.V.
– notice: Copyright © 2017 Elsevier B.V. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.ijpharm.2017.03.087
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-3476
EndPage 417
ExternalDocumentID 10_1016_j_ijpharm_2017_03_087
28373100
S0378517317302739
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
5GY
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AATCM
AAXUO
ABFNM
ABFRF
ABJNI
ABMAC
ABOCM
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SPCBC
SSP
SSZ
T5K
TEORI
~02
~G-
AAQFI
AAXKI
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
.GJ
29J
3O-
53G
5VS
AAQXK
AAYXX
ABXDB
ACRPL
ADMUD
ADNMO
AFJKZ
ASPBG
AVWKF
AZFZN
CITATION
FEDTE
FGOYB
G-2
HMT
HVGLF
HZ~
R2-
SEW
SPT
WUQ
ZXP
7X8
ID FETCH-LOGICAL-c431t-5c3f12d33f70cd017ff297dc9973c2531298fa16a125070dcb60322fe68563503
IEDL.DBID .~1
ISSN 0378-5173
IngestDate Fri Oct 25 01:29:19 EDT 2024
Fri Dec 06 02:11:14 EST 2024
Sat Sep 28 08:49:14 EDT 2024
Fri Feb 23 02:29:54 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords LbL-AuNP
PVP
MTT
SA
SC
DMEM
Iontophoresis
FITC
PDI
DSC
FBS
FTIR
Co-delivery
Cy3
Gold nanoparticle
PBS
IM
VEGF
STAT3
Melanoma
Imatinib mesylate
DAPI
PKC
siRNA
PAMAM
STAT3 siRNA
CS
RP-HPLC
Language English
License Copyright © 2017 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c431t-5c3f12d33f70cd017ff297dc9973c2531298fa16a125070dcb60322fe68563503
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 28373100
PQID 1884165270
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_1884165270
crossref_primary_10_1016_j_ijpharm_2017_03_087
pubmed_primary_28373100
elsevier_sciencedirect_doi_10_1016_j_ijpharm_2017_03_087
PublicationCentury 2000
PublicationDate 2017-06-20
PublicationDateYYYYMMDD 2017-06-20
PublicationDate_xml – month: 06
  year: 2017
  text: 2017-06-20
  day: 20
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle International journal of pharmaceutics
PublicationTitleAlternate Int J Pharm
PublicationYear 2017
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Smalley, Sondak, Weber (bib0165) 2009; 24
Long, Stroyakovskiy, Gogas, Levchenko, de Braud, Larkin (bib0110) 2014; 371
DeVita, Serpick, Carbone (bib0040) 1970; 73
Gupta, Sung, Prasad, Webb, Aggarwal (bib0060) 2013; 34
Russo, Ficili, Candido, Pezzino, Guarneri, Biondi (bib0150) 2014; 45
Huber, Pereira, Ramos, Rezende, Emery, Sobral (bib0075) 2015; 11
Adam (bib0005) 2003; 14
Guy, Kalia, Delgado-Charro, Merino, Lopez, Marro (bib0065) 2000; 64
Brown, Giaccia (bib0025) 1998; 58
Johnson, Sosman (bib0080) 2015; 1
Maverakis, Cornelius, Bowen, Phan, Patel, Fitzmaurice (bib0125) 2015; 95
Cao, Chu, Kwan, Su, Yu, Cheng (bib0030) 2016; 6
Rosen, Marcove, Caparros, Niremberg, Kosloff, Huvos (bib0140) 1979; 43
Alshamsan, Hamdy, Samuel, El-Kadi, Lavasanifar, Uludağ (bib0010) 2010; 31
Koivunen, Aaltonen, Peltonen (bib0085) 2006; 235
Hodi, Corless, Giobbie-Hurder, Fletcher, Zhu, Marino-Enriquez (bib0070) 2013; 31
Barry (bib0015) 2001; 14
Soffietti, Kocher, Abacioglu, Villa, Fauchon, Baumert (bib0170) 2013; 31
Begley, Ellis (bib0020) 2012; 28
Mandapalli, Labala, Vanamala, Koranglekar, Sakimalla, Venuganti (bib0120) 2014; 21
Kwong, Davies (bib0090) 2014; 33
Labala, Mandapalli, Kurumaddali, Venuganti (bib0095) 2015; 12
Liu, Cao, Wu, Sullivan, Shen, Ryu (bib0105) 2013; 133
Gottesman (bib0050) 2002; 53
Gray-Schopfer, Wellbrock, Marais (bib0055) 2007; 445
Zhao, Zhang, Liu, Wang, Shen, Yang (bib0180) 2010; 27
Longo, Young, Wesley, Hubbard, Duffey, Jaffe (bib0115) 1986; 4
Venuganti, Saraswathy, Dwivedi, Kaushik, Perumal (bib0175) 2015; 7
Shain, Bastian (bib0155) 2016; 16
Cosco, Paolino, Maiuolo, Marzio, Carafa, Ventura (bib0035) 2015; 487
McGill, Horstmann, Widlund, Du, Motyckova, Nishimura (bib0130) 2002; 109
Shen, Sun, Xu, Yin, Zhang, Wang (bib0160) 2013; 34
Prausnitz, Langer (bib0135) 2008; 26
Ferlay, Soerjomataram, Dikshit, Eser, Mathers, Rebelo (bib0045) 2015; 136
Rudzinski, Aminabhavi (bib0145) 2010; 399
Labala, Jose, Venuganti (bib0100) 2016; 146
Huber (10.1016/j.ijpharm.2017.03.087_bib0075) 2015; 11
Liu (10.1016/j.ijpharm.2017.03.087_bib0105) 2013; 133
Soffietti (10.1016/j.ijpharm.2017.03.087_bib0170) 2013; 31
Barry (10.1016/j.ijpharm.2017.03.087_bib0015) 2001; 14
Ferlay (10.1016/j.ijpharm.2017.03.087_bib0045) 2015; 136
Labala (10.1016/j.ijpharm.2017.03.087_bib0100) 2016; 146
Johnson (10.1016/j.ijpharm.2017.03.087_bib0080) 2015; 1
Prausnitz (10.1016/j.ijpharm.2017.03.087_bib0135) 2008; 26
Cosco (10.1016/j.ijpharm.2017.03.087_bib0035) 2015; 487
Mandapalli (10.1016/j.ijpharm.2017.03.087_bib0120) 2014; 21
Shain (10.1016/j.ijpharm.2017.03.087_bib0155) 2016; 16
Gupta (10.1016/j.ijpharm.2017.03.087_bib0060) 2013; 34
Long (10.1016/j.ijpharm.2017.03.087_bib0110) 2014; 371
Gray-Schopfer (10.1016/j.ijpharm.2017.03.087_bib0055) 2007; 445
Longo (10.1016/j.ijpharm.2017.03.087_bib0115) 1986; 4
Zhao (10.1016/j.ijpharm.2017.03.087_bib0180) 2010; 27
Alshamsan (10.1016/j.ijpharm.2017.03.087_bib0010) 2010; 31
Rosen (10.1016/j.ijpharm.2017.03.087_bib0140) 1979; 43
Russo (10.1016/j.ijpharm.2017.03.087_bib0150) 2014; 45
Kwong (10.1016/j.ijpharm.2017.03.087_bib0090) 2014; 33
Maverakis (10.1016/j.ijpharm.2017.03.087_bib0125) 2015; 95
DeVita (10.1016/j.ijpharm.2017.03.087_bib0040) 1970; 73
Smalley (10.1016/j.ijpharm.2017.03.087_bib0165) 2009; 24
Venuganti (10.1016/j.ijpharm.2017.03.087_bib0175) 2015; 7
Rudzinski (10.1016/j.ijpharm.2017.03.087_bib0145) 2010; 399
Shen (10.1016/j.ijpharm.2017.03.087_bib0160) 2013; 34
Brown (10.1016/j.ijpharm.2017.03.087_bib0025) 1998; 58
McGill (10.1016/j.ijpharm.2017.03.087_bib0130) 2002; 109
Cao (10.1016/j.ijpharm.2017.03.087_bib0030) 2016; 6
Labala (10.1016/j.ijpharm.2017.03.087_bib0095) 2015; 12
Koivunen (10.1016/j.ijpharm.2017.03.087_bib0085) 2006; 235
Begley (10.1016/j.ijpharm.2017.03.087_bib0020) 2012; 28
Hodi (10.1016/j.ijpharm.2017.03.087_bib0070) 2013; 31
Guy (10.1016/j.ijpharm.2017.03.087_bib0065) 2000; 64
Gottesman (10.1016/j.ijpharm.2017.03.087_bib0050) 2002; 53
Adam (10.1016/j.ijpharm.2017.03.087_bib0005) 2003; 14
References_xml – volume: 34
  start-page: 1581
  year: 2013
  end-page: 1590
  ident: bib0160
  article-title: Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles
  publication-title: Biomaterials
  contributor:
    fullname: Wang
– volume: 445
  start-page: 851
  year: 2007
  end-page: 857
  ident: bib0055
  article-title: Melanoma biology and new targeted therapy
  publication-title: Nature
  contributor:
    fullname: Marais
– volume: 399
  start-page: 1
  year: 2010
  end-page: 11
  ident: bib0145
  article-title: Chitosan as a carrier for targeted delivery of small interfering RNA
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Aminabhavi
– volume: 53
  start-page: 615
  year: 2002
  end-page: 627
  ident: bib0050
  article-title: Mechanisms of cancer drug resistance
  publication-title: Annu. Rev. Med.
  contributor:
    fullname: Gottesman
– volume: 34
  start-page: 508
  year: 2013
  end-page: 517
  ident: bib0060
  article-title: Cancer drug discovery by repurposing: teaching new tricks to old dogs
  publication-title: Trends Pharmacol. Sci.
  contributor:
    fullname: Aggarwal
– volume: 31
  start-page: 3182
  year: 2013
  end-page: 3190
  ident: bib0070
  article-title: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Marino-Enriquez
– volume: 16
  start-page: 345
  year: 2016
  end-page: 358
  ident: bib0155
  article-title: From melanocytes to melanomas
  publication-title: Nat. Rev. Cancer
  contributor:
    fullname: Bastian
– volume: 12
  start-page: 878
  year: 2015
  end-page: 888
  ident: bib0095
  article-title: Layer-by-layer polymer coated gold nanoparticles for topical delivery of imatinib mesylate to treat melanoma
  publication-title: Mol. Pharm.
  contributor:
    fullname: Venuganti
– volume: 33
  start-page: 1
  year: 2014
  end-page: 9
  ident: bib0090
  article-title: Targeted therapy for melanoma: rational combinatorial approaches
  publication-title: Oncogene
  contributor:
    fullname: Davies
– volume: 14
  start-page: 101
  year: 2001
  end-page: 114
  ident: bib0015
  article-title: Novel mechanisms and devices to enable successful transdermal drug delivery
  publication-title: Eur. J. Pharm. Sci.
  contributor:
    fullname: Barry
– volume: 95
  start-page: 516
  year: 2015
  end-page: 527
  ident: bib0125
  article-title: Metastatic melanoma – a review of current and future treatment options
  publication-title: Acta Derm. Venereol.
  contributor:
    fullname: Fitzmaurice
– volume: 43
  start-page: 2163
  year: 1979
  end-page: 2177
  ident: bib0140
  article-title: The rationale for preoperative chemotherapy and delayed surgery
  publication-title: Cancer
  contributor:
    fullname: Huvos
– volume: 27
  start-page: 203
  year: 2010
  end-page: 212
  ident: bib0180
  article-title: Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery
  publication-title: Med. Oncol.
  contributor:
    fullname: Yang
– volume: 235
  start-page: 1
  year: 2006
  end-page: 10
  ident: bib0085
  article-title: Protein kinase C (PKC) family in cancer progression
  publication-title: Cancer Lett.
  contributor:
    fullname: Peltonen
– volume: 26
  start-page: 1261
  year: 2008
  end-page: 1268
  ident: bib0135
  article-title: Transdermal drug delivery
  publication-title: Nat. Biotechnol.
  contributor:
    fullname: Langer
– volume: 31
  start-page: 65
  year: 2013
  end-page: 72
  ident: bib0170
  article-title: A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Baumert
– volume: 31
  start-page: 1420
  year: 2010
  end-page: 1428
  ident: bib0010
  article-title: The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine
  publication-title: Biomaterials
  contributor:
    fullname: Uludağ
– volume: 64
  start-page: 129
  year: 2000
  end-page: 132
  ident: bib0065
  article-title: Iontophoresis: electrorepulsion and electroosmosis
  publication-title: J. Control. Release
  contributor:
    fullname: Marro
– volume: 487
  start-page: 1
  year: 2015
  end-page: 10
  ident: bib0035
  article-title: Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Ventura
– volume: 21
  start-page: 605
  year: 2014
  end-page: 614
  ident: bib0120
  article-title: Influence of charge on encapsulation and release behavior of small molecules in self-assembled layer-by-layer microcapsules
  publication-title: Drug Deliv.
  contributor:
    fullname: Venuganti
– volume: 7
  start-page: 3903
  year: 2015
  end-page: 3914
  ident: bib0175
  article-title: Topical gene silencing by iontophoretic delivery of an antisense oligonucleotide-dendrimer nanocomplex: the proof of concept in a skin cancer mouse model
  publication-title: Nanoscale
  contributor:
    fullname: Perumal
– volume: 371
  start-page: 1877
  year: 2014
  end-page: 1888
  ident: bib0110
  article-title: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Larkin
– volume: 45
  start-page: 516
  year: 2014
  end-page: 524
  ident: bib0150
  article-title: Emerging targeted therapies for melanoma treatment (Review)
  publication-title: Int. J. Oncol.
  contributor:
    fullname: Biondi
– volume: 58
  start-page: 1408
  year: 1998
  end-page: 1416
  ident: bib0025
  article-title: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy
  publication-title: Cancer Res.
  contributor:
    fullname: Giaccia
– volume: 73
  start-page: 881
  year: 1970
  end-page: 895
  ident: bib0040
  article-title: Combination chemotherapy in the treatment of advanced Hodgkin's disease
  publication-title: Ann. Intern. Med.
  contributor:
    fullname: Carbone
– volume: 6
  start-page: 21731
  year: 2016
  ident: bib0030
  article-title: Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma
  publication-title: Sci. Rep.
  contributor:
    fullname: Cheng
– volume: 133
  start-page: 2041
  year: 2013
  end-page: 2049
  ident: bib0105
  article-title: Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas
  publication-title: J. Invest. Dermatol.
  contributor:
    fullname: Ryu
– volume: 24
  start-page: 643
  year: 2009
  end-page: 650
  ident: bib0165
  article-title: c-KIT signaling as the driving oncogenic event in sub-groups of melanomas
  publication-title: Histol. Histopathol.
  contributor:
    fullname: Weber
– volume: 1
  start-page: 380
  year: 2015
  end-page: 386
  ident: bib0080
  article-title: Therapeutic advances and treatment options in metastatic melanoma
  publication-title: JAMA Oncol.
  contributor:
    fullname: Sosman
– volume: 136
  start-page: E359
  year: 2015
  end-page: 86
  ident: bib0045
  article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
  publication-title: Int. J. Cancer
  contributor:
    fullname: Rebelo
– volume: 146
  start-page: 188
  year: 2016
  end-page: 197
  ident: bib0100
  article-title: Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma
  publication-title: Colloids Surf. B Biointerfaces
  contributor:
    fullname: Venuganti
– volume: 11
  start-page: 1975
  year: 2015
  end-page: 1988
  ident: bib0075
  article-title: Topical skin cancer therapy using doxorubicin-loaded cationic lipid nanoparticles and iontophoresis
  publication-title: J. Biomed. Nanotechnol.
  contributor:
    fullname: Sobral
– volume: 109
  start-page: 707
  year: 2002
  end-page: 718
  ident: bib0130
  article-title: Bcl2 regulation by the melanocyte master regulator mitf modulates lineage survival and melanoma cell viability
  publication-title: Cell
  contributor:
    fullname: Nishimura
– volume: 14
  start-page: 13
  year: 2003
  end-page: 16
  ident: bib0005
  article-title: Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases
  publication-title: Ann. Oncol.
  contributor:
    fullname: Adam
– volume: 28
  start-page: 531
  year: 2012
  end-page: 533
  ident: bib0020
  article-title: Drug development: raise standards for preclinical cancer research
  publication-title: Nature
  contributor:
    fullname: Ellis
– volume: 4
  start-page: 1295
  year: 1986
  end-page: 1306
  ident: bib0115
  article-title: Twenty years of MOPP therapy for Hodgkin's disease
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Jaffe
– volume: 399
  start-page: 1
  year: 2010
  ident: 10.1016/j.ijpharm.2017.03.087_bib0145
  article-title: Chitosan as a carrier for targeted delivery of small interfering RNA
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2010.08.022
  contributor:
    fullname: Rudzinski
– volume: 31
  start-page: 1420
  year: 2010
  ident: 10.1016/j.ijpharm.2017.03.087_bib0010
  article-title: The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2009.11.003
  contributor:
    fullname: Alshamsan
– volume: 235
  start-page: 1
  year: 2006
  ident: 10.1016/j.ijpharm.2017.03.087_bib0085
  article-title: Protein kinase C (PKC) family in cancer progression
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2005.03.033
  contributor:
    fullname: Koivunen
– volume: 24
  start-page: 643
  year: 2009
  ident: 10.1016/j.ijpharm.2017.03.087_bib0165
  article-title: c-KIT signaling as the driving oncogenic event in sub-groups of melanomas
  publication-title: Histol. Histopathol.
  contributor:
    fullname: Smalley
– volume: 64
  start-page: 129
  year: 2000
  ident: 10.1016/j.ijpharm.2017.03.087_bib0065
  article-title: Iontophoresis: electrorepulsion and electroosmosis
  publication-title: J. Control. Release
  doi: 10.1016/S0168-3659(99)00132-7
  contributor:
    fullname: Guy
– volume: 4
  start-page: 1295
  year: 1986
  ident: 10.1016/j.ijpharm.2017.03.087_bib0115
  article-title: Twenty years of MOPP therapy for Hodgkin's disease
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.1986.4.9.1295
  contributor:
    fullname: Longo
– volume: 53
  start-page: 615
  year: 2002
  ident: 10.1016/j.ijpharm.2017.03.087_bib0050
  article-title: Mechanisms of cancer drug resistance
  publication-title: Annu. Rev. Med.
  doi: 10.1146/annurev.med.53.082901.103929
  contributor:
    fullname: Gottesman
– volume: 31
  start-page: 3182
  year: 2013
  ident: 10.1016/j.ijpharm.2017.03.087_bib0070
  article-title: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.47.7836
  contributor:
    fullname: Hodi
– volume: 21
  start-page: 605
  year: 2014
  ident: 10.1016/j.ijpharm.2017.03.087_bib0120
  article-title: Influence of charge on encapsulation and release behavior of small molecules in self-assembled layer-by-layer microcapsules
  publication-title: Drug Deliv.
  doi: 10.3109/10717544.2013.867381
  contributor:
    fullname: Mandapalli
– volume: 34
  start-page: 1581
  year: 2013
  ident: 10.1016/j.ijpharm.2017.03.087_bib0160
  article-title: Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2012.10.057
  contributor:
    fullname: Shen
– volume: 6
  start-page: 21731
  year: 2016
  ident: 10.1016/j.ijpharm.2017.03.087_bib0030
  article-title: Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma
  publication-title: Sci. Rep.
  doi: 10.1038/srep21731
  contributor:
    fullname: Cao
– volume: 14
  start-page: 13
  year: 2003
  ident: 10.1016/j.ijpharm.2017.03.087_bib0005
  article-title: Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdg731
  contributor:
    fullname: Adam
– volume: 95
  start-page: 516
  year: 2015
  ident: 10.1016/j.ijpharm.2017.03.087_bib0125
  article-title: Metastatic melanoma – a review of current and future treatment options
  publication-title: Acta Derm. Venereol.
  doi: 10.2340/00015555-2035
  contributor:
    fullname: Maverakis
– volume: 109
  start-page: 707
  year: 2002
  ident: 10.1016/j.ijpharm.2017.03.087_bib0130
  article-title: Bcl2 regulation by the melanocyte master regulator mitf modulates lineage survival and melanoma cell viability
  publication-title: Cell
  doi: 10.1016/S0092-8674(02)00762-6
  contributor:
    fullname: McGill
– volume: 1
  start-page: 380
  year: 2015
  ident: 10.1016/j.ijpharm.2017.03.087_bib0080
  article-title: Therapeutic advances and treatment options in metastatic melanoma
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2015.0565
  contributor:
    fullname: Johnson
– volume: 43
  start-page: 2163
  year: 1979
  ident: 10.1016/j.ijpharm.2017.03.087_bib0140
  article-title: The rationale for preoperative chemotherapy and delayed surgery
  publication-title: Cancer
  doi: 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S
  contributor:
    fullname: Rosen
– volume: 11
  start-page: 1975
  year: 2015
  ident: 10.1016/j.ijpharm.2017.03.087_bib0075
  article-title: Topical skin cancer therapy using doxorubicin-loaded cationic lipid nanoparticles and iontophoresis
  publication-title: J. Biomed. Nanotechnol.
  doi: 10.1166/jbn.2015.2139
  contributor:
    fullname: Huber
– volume: 31
  start-page: 65
  year: 2013
  ident: 10.1016/j.ijpharm.2017.03.087_bib0170
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.41.0639
  contributor:
    fullname: Soffietti
– volume: 34
  start-page: 508
  year: 2013
  ident: 10.1016/j.ijpharm.2017.03.087_bib0060
  article-title: Cancer drug discovery by repurposing: teaching new tricks to old dogs
  publication-title: Trends Pharmacol. Sci.
  doi: 10.1016/j.tips.2013.06.005
  contributor:
    fullname: Gupta
– volume: 12
  start-page: 878
  year: 2015
  ident: 10.1016/j.ijpharm.2017.03.087_bib0095
  article-title: Layer-by-layer polymer coated gold nanoparticles for topical delivery of imatinib mesylate to treat melanoma
  publication-title: Mol. Pharm.
  doi: 10.1021/mp5007163
  contributor:
    fullname: Labala
– volume: 33
  start-page: 1
  year: 2014
  ident: 10.1016/j.ijpharm.2017.03.087_bib0090
  article-title: Targeted therapy for melanoma: rational combinatorial approaches
  publication-title: Oncogene
  doi: 10.1038/onc.2013.34
  contributor:
    fullname: Kwong
– volume: 133
  start-page: 2041
  year: 2013
  ident: 10.1016/j.ijpharm.2017.03.087_bib0105
  article-title: Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas
  publication-title: J. Invest. Dermatol.
  doi: 10.1038/jid.2013.32
  contributor:
    fullname: Liu
– volume: 73
  start-page: 881
  year: 1970
  ident: 10.1016/j.ijpharm.2017.03.087_bib0040
  article-title: Combination chemotherapy in the treatment of advanced Hodgkin's disease
  publication-title: Ann. Intern. Med.
  doi: 10.7326/0003-4819-73-6-881
  contributor:
    fullname: DeVita
– volume: 487
  start-page: 1
  issue: 489
  year: 2015
  ident: 10.1016/j.ijpharm.2017.03.087_bib0035
  article-title: Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2015.04.056
  contributor:
    fullname: Cosco
– volume: 28
  start-page: 531
  issue: 483
  year: 2012
  ident: 10.1016/j.ijpharm.2017.03.087_bib0020
  article-title: Drug development: raise standards for preclinical cancer research
  publication-title: Nature
  doi: 10.1038/483531a
  contributor:
    fullname: Begley
– volume: 26
  start-page: 1261
  year: 2008
  ident: 10.1016/j.ijpharm.2017.03.087_bib0135
  article-title: Transdermal drug delivery
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1504
  contributor:
    fullname: Prausnitz
– volume: 445
  start-page: 851
  year: 2007
  ident: 10.1016/j.ijpharm.2017.03.087_bib0055
  article-title: Melanoma biology and new targeted therapy
  publication-title: Nature
  doi: 10.1038/nature05661
  contributor:
    fullname: Gray-Schopfer
– volume: 27
  start-page: 203
  year: 2010
  ident: 10.1016/j.ijpharm.2017.03.087_bib0180
  article-title: Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-009-9192-1
  contributor:
    fullname: Zhao
– volume: 7
  start-page: 3903
  year: 2015
  ident: 10.1016/j.ijpharm.2017.03.087_bib0175
  article-title: Topical gene silencing by iontophoretic delivery of an antisense oligonucleotide-dendrimer nanocomplex: the proof of concept in a skin cancer mouse model
  publication-title: Nanoscale
  doi: 10.1039/C4NR05241B
  contributor:
    fullname: Venuganti
– volume: 16
  start-page: 345
  year: 2016
  ident: 10.1016/j.ijpharm.2017.03.087_bib0155
  article-title: From melanocytes to melanomas
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.37
  contributor:
    fullname: Shain
– volume: 58
  start-page: 1408
  year: 1998
  ident: 10.1016/j.ijpharm.2017.03.087_bib0025
  article-title: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy
  publication-title: Cancer Res.
  contributor:
    fullname: Brown
– volume: 136
  start-page: E359
  year: 2015
  ident: 10.1016/j.ijpharm.2017.03.087_bib0045
  article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.29210
  contributor:
    fullname: Ferlay
– volume: 146
  start-page: 188
  year: 2016
  ident: 10.1016/j.ijpharm.2017.03.087_bib0100
  article-title: Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma
  publication-title: Colloids Surf. B Biointerfaces
  doi: 10.1016/j.colsurfb.2016.05.076
  contributor:
    fullname: Labala
– volume: 45
  start-page: 516
  year: 2014
  ident: 10.1016/j.ijpharm.2017.03.087_bib0150
  article-title: Emerging targeted therapies for melanoma treatment (Review)
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2014.2481
  contributor:
    fullname: Russo
– volume: 371
  start-page: 1877
  year: 2014
  ident: 10.1016/j.ijpharm.2017.03.087_bib0110
  article-title: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1406037
  contributor:
    fullname: Long
– volume: 14
  start-page: 101
  year: 2001
  ident: 10.1016/j.ijpharm.2017.03.087_bib0015
  article-title: Novel mechanisms and devices to enable successful transdermal drug delivery
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/S0928-0987(01)00167-1
  contributor:
    fullname: Barry
SSID ssj0006213
Score 2.5502627
Snippet [Display omitted] Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of...
Co-delivery of chemotherapeutic agents improve anti-tumor efficacy and reduce cancer resistance. Here, we report development of layer-by-layer assembled gold...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 407
SubjectTerms Animals
Cell Line, Tumor
Co-delivery
Gold
Gold nanoparticle
Imatinib mesylate
Imatinib Mesylate - administration & dosage
Iontophoresis
Melanoma
Melanoma, Experimental - genetics
Melanoma, Experimental - therapy
Metal Nanoparticles - chemistry
Mice
RNA, Small Interfering - administration & dosage
STAT3 siRNA
STAT3 Transcription Factor - genetics
Title Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles
URI https://dx.doi.org/10.1016/j.ijpharm.2017.03.087
https://www.ncbi.nlm.nih.gov/pubmed/28373100
https://search.proquest.com/docview/1884165270
Volume 525
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEBYhufRS-q7TNkyh5JS15dU-jyYkuC01oXEgN6HHKl3jaJfYpviS356ZfcQEWgo97rIPoZFmPjHffMPYF4NROnPaBA7RcBBFsQq0ilygNR7jxmmaRRHVDv-YJdOr6Nt1fL3HTvtaGKJVdr6_9emNt-7ujLrZHNVlObrkomksjwGQcm-CiviimFMXg-H9juaRhF2LZDwt0dO7Kp7RYlguahKIJoZX2midErPuz_Hpb_iziUPnL9jzDkDCpB3jS7ZX-Ffs-KJVoN6ewHxXULU6gWO42GlTb1-z361aMbo4uC2Wyle3CgwZ_g5Wm7ojxXrQWyhJ2KD-1VY5gqkCWyyJw7GFysHlfDIXsCp_ziagvIWScK8vNRCN_gZuqqUFj1-ve97dG3Z1fjY_nQZd74XAIKRYB7ERbhxaIVzKjcXpcS7MU2vyPBUmxI0b5plT40QhQEKvYY1OOPoGVyRZjBiGi7ds31e-eM-gcHimi0yeOKrbzRJt01BzbRHbKwJMAzbsZ1zWrcSG7LlnC9mZSJKJJBcSTTRgWW8X-WStSAwD_3r1c29HifuIkiPKF9VmJccZJWDjMOUD9q418ONoSCGIEiGH___jD-wZXRHJLOQf2f76blN8Qjiz1kfNej1iB5Ov36ezB8ys9aM
link.rule.ids 314,780,784,4502,24116,27924,27925,45585,45679
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF7S9NBeSvp208cUSk6RLWv1PJqQ4LaJCY0CuS370KYyzkrENsGX_PbO6FETaCn0qucyszvzLfPNt4x90ZilU6u0ZxENe2EYSU_J0HpK4TZunCRpGFLv8Nksnl6G366iqx121PfCEK2yi_1tTG-idXdl1FlzVJfl6MLnzcHymACp9sazR-xxGCH6xUk9vN_yPOKgOyMZt0v0-LaNZzQflvOaFKKJ4pU0YqdErftzgvobAG0S0ckee9YhSJi0g3zOdgr3gh2ctxLUm0PItx1Vy0M4gPOtOPXmJbtr5YoxxsFNsZCuupGgyfO3sFzXHSvWgdpAScoG9c-2zRF05ZliQSSODVQWLvJJzmFZ_phNQDoDJQFfVyogHv01XFcLAw6_XvfEu1fs8uQ4P5p63eELnkZMsfIize04MJzbxNcGzWNtkCVGZ1nCdYArN8hSK8exRISEYcNoFfsYHGwRpxGCGJ-_ZruucsVbBoXFTV2os9hS424aK5MEylcGwb0kxDRgw97iom41NkRPPpuLzkWCXCR8LtBFA5b2fhEPJovAPPCvVz_3fhS4kKg6Il1RrZdinFIFNgoSf8DetA7-PRqSCKJKyLv___En9mSan52K06-z7_vsKd0hxlngv2e7q9t18QGxzUp9bObuL5C290A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effective+melanoma+cancer+suppression+by+iontophoretic+co-delivery+of+STAT3+siRNA+and+imatinib+using+gold+nanoparticles&rft.jtitle=International+journal+of+pharmaceutics&rft.au=Labala%2C+Suman&rft.au=Jose%2C+Anup&rft.au=Chawla%2C+Sumeet+Rajesh&rft.au=Khan%2C+Mohammed+Shareef&rft.date=2017-06-20&rft.eissn=1873-3476&rft.volume=525&rft.issue=2&rft.spage=407&rft.epage=417&rft_id=info:doi/10.1016%2Fj.ijpharm.2017.03.087&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5173&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5173&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5173&client=summon